U.S. Personal Products Stock News

NasdaqGS:SSYS
NasdaqGS:SSYSMachinery

Assessing Stratasys (SSYS) Valuation After Subaru Adoption Of High Speed 3D Printing Head

Stratasys (SSYS) is back in focus after Subaru of America reported using the company’s new T25 High Speed Head on the F770 3D printer to cut tooling time and costs in automotive workflows. See our latest analysis for Stratasys. The Subaru win arrives after a strong 30 day share price return of 24.2% and a 7 day share price return of 8.4%, although the 5 year total shareholder return of a 70.7% loss shows longer term momentum has been weak. If this kind of real world adoption catches your eye,...
NYSE:EGY
NYSE:EGYOil and Gas

Does VAALCO Energy (EGY) Hitting Peak 2025 Sales Guidance Redefine Its Operational Credibility?

VAALCO Energy, Inc. recently reported that full-year 2025 sales volumes reached about 22,100 working interest barrels of oil equivalent per day, at the top of its guidance range, while production averaged approximately 21,150 working interest barrels of oil equivalent per day, landing near the midpoint of prior expectations. This combination of sales at the high end of guidance and production in line with targets suggests the company executed its 2025 operating plan efficiently and converted...
NasdaqGS:TLN
NasdaqGS:TLNRenewable Energy

Is Talen Energy (TLN) Still Attractive After A 58% One Year Share Price Gain

If you are wondering whether Talen Energy's share price still reflects good value after a strong run, this article will walk through what the current market price might be implying. The stock closed at US$371.66, with returns of 0.2% over the last 7 days, 5.6% over the last 30 days, a 6.3% decline year to date, and 58.2% over the last year. This naturally raises questions about how much future upside or risk is already priced in. Recent company updates and sector news have kept attention on...
NasdaqCM:MREO
NasdaqCM:MREOBiotechs

A Look At Mereo BioPharma Group (MREO) Valuation After Mixed Setrusumab Phase 3 Results And Cash Runway Update

Mereo BioPharma Group (NasdaqCM:MREO) has come into focus after releasing mixed Phase 3 results for setrusumab in osteogenesis imperfecta, along with a cash runway update to mid-2027 and progress on its alvelestat and vantictumab programs. See our latest analysis for Mereo BioPharma Group. The mixed Phase 3 readout and cash runway update come after a volatile stretch for the stock, with a 7 day share price return of 29.45% following a 30 day share price return decline of 66.67%, and a 1 year...
NasdaqGS:CHYM
NasdaqGS:CHYMDiversified Financial

Chime Financial (CHYM) Is Down 6.1% After Slower Growth And Shift To In-House Payments Strategy

Recently, Chime Financial reported slowing growth and sequential declines in purchase volume, prompting investors to reassess the fintech’s competitive position and outlook. At the same time, Chime is pushing into higher-margin products, in-house payment processing, and AI-driven features to broaden its customer base and improve unit economics. We’ll now examine how Chime’s shift to its own payment processing platform could influence the company’s investment narrative and long-term...
NasdaqGS:FYBR
NasdaqGS:FYBRTelecom

Frontier Communications Parent (FYBR) Valuation Check As Price-To-Sales Premium Contrasts With DCF Discount

Frontier Communications Parent (FYBR) has attracted attention after recent share moves, with the stock last closing at $38.44. Investors are weighing this price against the company’s fundamentals and its recent return profile. See our latest analysis for Frontier Communications Parent. Putting the latest move into context, Frontier’s recent 1-day, 7-day and 90-day share price returns, alongside an 8.28% 1-year total shareholder return and 34.88% 3-year total shareholder return, point to...